Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile

Stock Information for Moleculin Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Moleculin Biotech Inc.

Scalable Biotech Manufacturing Unlocks a $14B Market
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
Moleculin to Present at 38th Annual ROTH Conference
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.